---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-066821"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2026-06-09T20:30:15+00:00"
generated_at: "2026-06-09T20:32:20.464273+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# MoonLake shareholders approve 5M share increase to equity plan at 2026 AGM

## Summary
- Shareholders approved amendment to 2022 Equity Incentive Plan, adding 5,000,000 Class A shares for awards.
- Plan now includes one-year minimum vesting requirement, revised director compensation limits, and term through 2036.
- Director Spike Loy re-elected with 92.4% of votes cast; auditor Baker Tilly ratified with 99.9% support.
- Advisory vote on executive compensation passed with 98.6% of votes cast in favor.
- Total shares authorized under the plan now 9,353,948, subject to adjustment provisions.

## SEC filing metadata
- accession: 0001213900-26-066821
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2026-06-09T20:30:15+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000121390026066821/0001213900-26-066821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000121390026066821/ea0294064-8k_moonlake.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-066821
- JSON: https://secwatch.observer/filing/0001213900-26-066821.json
- Plain text: https://secwatch.observer/filing/0001213900-26-066821.txt

## Key facts
- Shareholder Votes
  MoonLake Immunotherapeutics shareholders approved Election of Class I Director Nominee.
  - Proposal: director election
  - Outcome: passed
  source text: At the Annual Meeting, the Class I director nominee was elected and the other proposals voted on were approved. The final voting results are set forth below: Votes For Votes Withheld Broker Non-Votes Proposal 1. Election of the Class I Director Nominee ● Spike Loy 47,222,233 3,889,131 10,761,142
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821586/000121390026066821/0001213900-26-066821-index.htm
- Shareholder Votes
  MoonLake Immunotherapeutics shareholders approved Approval of an Amendment and Restatement of the 2022 Equity Incentive Plan.
  - Proposal: equity plan
  - Outcome: passed
  source text: Proposal 4. Approval of an Amendment and Restatement of the 2022 Equity Incentive Plan 50,599,032 498,186 14,146 10,761,142
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821586/000121390026066821/0001213900-26-066821-index.htm
- Shareholder Votes
  MoonLake Immunotherapeutics shareholders approved Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor.
  - Proposal: auditor ratification
  - Outcome: passed
  source text: Proposal 2. Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor 61,831,463 17,522 23,521 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821586/000121390026066821/0001213900-26-066821-index.htm
- Shareholder Votes
  MoonLake Immunotherapeutics shareholders approved Advisory Vote on Executive Compensation.
  - Proposal: say on pay
  - Outcome: passed
  source text: Proposal 3. Advisory Vote on Executive Compensation 50,365,168 731,158 15,038 10,761,142
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821586/000121390026066821/0001213900-26-066821-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.